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Ever since the earliest
 use of platinum –based drugs having been given to 
cancer patients, there has been recognition of an increased 
incidence of cardiac failure and cardiomyopathy [ see 
1-3]. Radiation- based therapy, either alone or more likely 
combined with chemotherapeutic drugs, has also been 
associated with cardiac failure and cardiomyopathy [4-
11].  Although a patient may want to accept temporary 
occurrence of cardiac and cardiovascular dysfunctions 
of various types (e.g., QT prolongation, left ventricular 
dysfunctions, arrhythmias, fibrillations[ e.g., atrial 
fibrillation-AF], coronary ischemia, coronary vasospasm, 
pulmonary hypertension, myocardial infarctions, elevation 
in arterial blood pressure, congestive heart failure,  venous 
and arterial thrombo-embolism, diastolic or systolic 
dysfunctions, coronary arterial inflammations, pericardial 
disease, and/or accelerated atherogenesis, etc.) for a higher 
potential of a cancer cure, the risk for cardiac failure or 
cardiomyopathy increases with dosing of many platinum-
based chemotherapeutic drugs(PBCDs), aminoglycosides 
like amphotericin B as well as anthracyclines(e.g., 
doxorubicin), and  antimetabolite agents like 
5-fluorouracil [1-11]. It should be pointed out that many 
of these cardiovascular events occur after prolonged 
PCBDs , amphotericin B,  anthracyclines, alkaloids(e.g., 
vinblastine), anti-tumor antibiotics(e.g., bleomycin) , 
cyclophosphamide or radiation treatment. Even treatment 
with a variety of the newer anti-angiogenic drugs such as the 
antibodies like bevacizumab, sorafenib, and sunitinib have 
been associated with cardio-and cardiovascular toxicities 
similar to the PBCDs, anthracyclines,  amphotericin 
B and cyclophosphamide  [4-11]. More recently, use of 
the small-molecule tyrosine kinase inhibitors, multiple 
tyrosine kinase inhibitors, monoclonal antibodies to 
HERS2, as well as proteasome inhibitors (e.g., bortezomib, 
carfilzomib) have also been associated with increased 
incidences of cardio-toxicities [5-11]. Why, however, do 
these structurally, diverse chemotherapeutic drugs and 
radiation induce cardiac toxicity, unexplained coronary 
vasospasm, congestive heart failure, cardiomyopathy, and 
complete cardiac failure followed by death?
 Almost four decades ago [13], two of us pointed 
out that there was a scattered number of clinical studies 
that were beginning to indicate that at least three of the 
chemotherapeutic  drugs (i.e., cisplatin, vinbastine, and 
bleomycin) appeared to suggest that chemotherapeutic 
anticancer drugs may deplete the body of magnesium(Mg) 
[for references and review, see 1-3,12 ]. Ever since 
we suggested the potential danger of these drugs to the 
heart and cardiovascular system[13], a growing body of 
evidence has borne-out these initial dangers to cancer 
patients[e.g., for reviews see 4-11]. It appears from recent 
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studies that cancer patients receiving cardiac transplants, 
who had taken chemotherapeutic drugs and/or radiation 
often showed unexplained, worsened depletion of Mg 
[for recent review, see 12]. How and why could depletion 
of body Mg stores, and Mg depletion from the heart and 
blood vessels, cause cardiac arrhythmias, elevated arterial 
blood pressure , prolonged QT intervals, coronary arterial 
vasospasm, myocardial ischemic events, myocardial 
infarctions, and sudden-cardiac death (SCD) ?
Relationship of Mg to Cardiac 
Stabilization and Function, Hypertension, 
Cardiomyopathy, and Sudden-Cardiac Death 
 Over the past four decades, evidence has 
accumulated to indicate that daily dietary deficiency of 
Mg intake and/or errors in Mg metabolism pose serious 
risks for development of AF, hypertension, atherosclerosis, 
inflammation, endothelial cell dysfunctions, dysfunctions 
of cardiac bioenergetics, coronary arterial vasospasm, 
myocardial infarctions, coronary ischemic events, 
cardiomyopathy, cardiac failure, strokes and SCD[13-
53], whereas higher than normal Mg intake is found to be 
associated with decreased or ameliorated AFs, myocardial 
infarctions, hypertension, strokes, and incidences of 
cardiomyopathies and SCD[16-33]. Moreover, there is a 
growing, scattered literature which suggests that cancer 
patients pretreated with Mg have less cardiotoxic events 
after chemo-or radiation treatment [2, 12]. Mg is a co-
factor for more than 500 enzymes, and is the second most 
abundant intracellular cation after potassium and is a 
critical requirement for regulation of Ca2+, Na+/K+ transport 
across all cell membranes [54]. It is vital in numerous 
physiological, cellular and biochemical reactions including 
carbohydrate, lipid, protein, DNA and RNA metabolism, 
membrane ion transport, among other pathways [19,22,27-
33,36,37,42,46,49,51,52,54 ]. Several epidemiologic 
studies in North America and Europe have shown that 
people consuming Western-type diets are low in Mg 
content(i.e., 30-45 % of the RDA for Mg) [13,54-59]; most 
such studies in the USA show that 60-80% of Americans are 
consuming 185-235 mg/day of Mg [31,51,54-59]. In1900, 
in contrast, most Americans were consuming 450-550 mg/
day of Mg [ 31,51 ]. Low Mg content of drinking water , 
found in areas of soft-water and Mg-poor soil, is associated 
with high incidences of ischemic heart disease(IHD), 
atherosclerosis, coronary ischemia, hypertension, and 
SCD [13-17,21,28,31,51,55,56]. The myocardial level of 
Mg has consistently been observed to be lower in subjects 
dying from IHD and SCD in soft-water areas than those 
subjects living in hard-water areas [14-17, 21,28,31,55, 
56 ]. More than 45 years ago, two of us demonstrated 
that Mg2+ behaves as a natural calcium channel blocker 
in both cardiac and vascular smooth muscle (VSM) cells 
[19, 60-65]. We also showed that Mg behaves as a natural 
statin drug as it can lower cholesterol and trigyceride 
levels as well as act as a powerful vasodilator in the 
microcirculation, on coronary arteries and arterioles, and 
as cardiac muscle relaxant [16-19,23,27-33,36,48,50,66-
68; unpublished findings ]. Hypermagnesemic diets have 
been shown to ameliorate hypertension and atherogenesis 
as well as lower the incidences of arrhythmias and strokes 
[13, 20,28,31-33,44,49,51, 69-86 ]. 
Use of Mg2+ Ion-Selective Electrodes in Diseased 
Patients
 Using sensitive and newly-designed specific Mg2+-
ion selective electrodes, our laboratories demonstrated 
that patients with hypertension, IHD, cardiac failure, 
ischemic and hemorrhagic strokes, blood loss, and 
atherogenesis exhibit significant reductions in plasma/
serum/whole blood levels of ionized Mg [39, 40,51, 87-
101]. Other experiments on cancer patients receiving a 
variety of the chemotherapeutic drugs mentioned, above, 
also demonstrate marked reductions in serum ionized 
Mg levels[for reviews, see 102].   We have shown that 
dietary deficiencies in Mg in rabbits and rats cause 
vascular remodeling(i.e., arteriolar wall hypertrophy 
and alterations in the matrices of the vascular walls) 
concomitant with atherogenesis, high blood pressure, and 
microvascular vessel vasospasm . Such events in cancer 
patients receiving the variety of chemotherapeutic drugs, 
discussed above, could easily account for cardiotoxic and 
cardiovascular disturbances seen with these drugs leading 
to cardiomyopathy , cardiac failure, and SCD. 
Low [Mg2+]0 Environments Result in 
Concentration-dependent Coronary Arterial 
Vasospasm, Increased Vascular Reactivity 
to Endogenous Vasoconstrictor Agents, and 
Dysfunctions of Cardiac Hemodynamics 
 Approximately 40 years ago, our group found that 
declining levels of extracellular Mg2+([Mg2+]0) resulted in 
concentration-dependent constriction and vasospasm of 
small (<100 um in diameter), medium and large coronary 
arteries excised from dogs, sheep, baboons and rats . These 
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low [Mg2+]0-induced vasospasms could only be attenuated 
or inhibited with elevated concentrations of Mg2+. In 
addition, we noted that low [Mg2+]0 levels enhanced 
vasoconstrictor responses to a variety of vasoactive and 
neurohumoral transmitters (e.g., angiotensin II, serotonin, 
norepinephrine, multiple peptides, etc.). We suggested, 
at that time, that low dietary levels of Mg could result in 
arrhythmias, IHD and SCD . Ever since these early studies 
were published, a number of clinical studies have been 
published which support our hypothesis . Using perfused , 
working rat hearts, we found that low levels of Mg2+ result in 
reductions in coronary flows, reductions in cardiac output, 
reductions in stroke volume and peak systolic pressure 
development, reductions in myocardial intracellular Mg2+ 
levels, reduction in myocardial levels of ATP, increased 
levels of inorganic phosphate, acidification of atrial and 
ventricular myocytes, Ca2+ overload, and generation of 
powerful reactive oxygen and nitrogen species (e.g,H2O2, 
hypochlorite ions, hydroxyl ions, ferrylmyoglobin, etc.) . 
Taken together, such results, in themselves, could account 
for chemotherapeutic drug-induced AF, myocardial 
ischemia, coronary vasospasm, prolonged QT intervals, 
increased vascular tone and pressures, IHD, and SCD. But, 
added to these events are the multiple effects of low [Mg2+]0 
on intravessel inflammatory dynamics such as leukocytic, 
monocyte and platelet sticking to endothelial cell walls, 
increased postcapillary changes in vascular permeability, 
vasoconstriction in the coronary microcirculation, 
increased release of cytokines and chemokines, release 
of antibodies of diverse types, and release of complement 
proteins.
Mg2+ Regulates Sphingolipid Pathways in Cardiac 
and Vascular Smooth Muscle Cells
 Recent studies, from our laboratories, indicate 
that Mg2+ can modulate sphingolipid pathways in both 
cardiac and vascular smooth muscle (VSM) cells . 
Ceramides are sphingolipids known to be released as 
a consequence of sphingomyelinases (SMases) acting 
on sphingomyelin(SM), a component of all extra- and 
intracellular cell membranes, or as a consequence of the 
activation of serine palmitoyl transferase 1 and 2 (SPT 1 
and SPT 2) (a de novo synthetic pathway) . Ceramides are 
now known to play important, and key, roles in fundamental 
pathophysiological processes such as inflammation, 
angiogenesis, atherogenesis, membrane-receptor 
functions, cell proliferation, microcirculatory functions, 
cell adhesion, immunogenic responses, excitation-
contraction coupling events in cardiac and VSM cells, and 
cell death (i.e., apoptosis) . An upregulation of SPT 1 and 
SPT 2 has been hypothesized to play an important role in 
apoptosis cell death events taking place in atherogenesis 
. Such upregulation could be quite pivotal in producing 
plaques on the endothelium of coronary vessels leading to 
ischemic events , IHD, and SCD observed in cancer patients 
treated with diverse chemotherapeutic agents . Working 
with perfused rat hearts, we have noted incremental rises 
in ceramides as the [Mg2+]0 was reduced concomitant with 
decreases in stroke volume, increased levels of lactic acid 
dehydrogenase and creatine phosphokinase, increased lipid 
peroxidation of cardiac muscle cells, reduction of cardiac 
intracellular pH, and generation of reactive- oxygen and 
nitrogen species . Preliminary experiments , with perfused 
hearts given increasing doses of doxorubicin yield very 
similar results [ unpublished findings].
 It is of considerable interest to note, here, that, 
experimentally, myocardial infarctions have recently been 
shown to be associated with rising levels of ceramides . 
In human subjects,it has been reported that stable angina 
pectoris, unstable angina pectoris, and acute myocardial 
infarction are also associated with rising levels of 
ceramides .  In some of these patients, a clear elevation in 
SMases was observed along with a reduction in SM .
 During the performance of our foregoing in vitro 
and in vivo low [Mg2+}0 experiments, using proton-nuclear 
magnetic resonance spectroscopy, we noted a rapid 
formation of platelet-activating factor (PAF) and PAF-like 
lipid molecules.
Mg2+-Deficient Environments Lead to Formation 
of PAF and PAF-like Lipids: Potential Significance 
to Chemotherapeutic – induced Ischemic Cardiac 
Events
 PAF is now known to play major roles in 
inflammatory responses, blood pressure and atherogenesis 
. In addition, PAF and PAF-like lipids are known to 
affect the heart and cardiac muscle cells in numerous 
ways For example, PAF can produce coronary arterial 
vasoconstriction, alter arterial blood pressure, increases 
coronary vascular resistance, release several lipid-like 
molecules from the heart, reduce cardiac output, decrease 
cardiac contractility, alter atrial and papillary muscle 
page 4 of 9ISSN:xxxx-xxxx SFJEM, an open access journal
Volume 1 · Issue 1 · 1000001SF J Emer Med
Citation: Burton M Altura (2017) Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is this 
a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?. SF J Emer Med1:1.
chronotropicity and membrane action potentials, as well 
as alter potassium currents in isolated cardiomyocytes. All 
of these attributes of PAF’s actions on the myocardium 
and the coronary vascular tree would be more than enough 
to cause profound atrial and ventricular fibrillation, 
and SCD. Moreover, a variety of the circulating blood-
formed elements (e.g., polymorph nuclear leukocytes, 
platelets, basophils, and macrophages) can elaborate 
PAF and PAF-like lipids. Recently, we have reported that 
coronary, cerebral and aortic vSM cells as well as atrial 
and ventricular cardiac myocytes can also elaborate PAF 
, particularly when the diverse cells are exposed to low 
[Mg2+]0 levels. A number of investigators employing 
intravital microscopy techniques, similar to those used 
in our laboratorieshave demonstrated that PAF increased 
the numbers of white blood cells in the microvessels 
concomitant with intense vasoconstriction-spasms with 
increasing concentrations of the putative lipid mediator (i.e., 
PAF), and less leukocyte rolling along the endothelial cell 
surfaces wth increased venular-postcapillary permeability 
Interestingly, we have found that ceramides can produce 
almost identical phenomena in a variety of microvascular 
beds, in vivo, when studied by high-resolution video 
microscopy . We believe rather firmly, that these older and 
newer experimental studies could be used to advance our 
hypothesis that generation and release of both PAF(and 
PAF-like lipids) and ceramides due, in large measure to 
chemotherapeutically- and diet-induced Mg-deficiency, 
are more than likely involved in generation of anti-cancer 
drug-induced cardiomyopathy, IHD, coronary vasospasm 
, and SCD.
Importance of Dietary Mg Supplementation for 
Prevention and Amelioration of Chemotherapeutic 
Anti-Cancer Drug –induced Cardiomyopathy, 
Cardiac Failure and SCD
 Over the past 30 years , our laboratories have 
been investigating the utility of using Mg2+ ion-selective 
electrodes and Mg-supplemented or naturally-occurring 
Mg-enriched spring waters to avoid the pitfalls of dietary-
and/or metabolically-induced Mg-deficient states which 
affect heart health . Our results, to date, with the Mg2+-
electrodes ( to accurately measure ionized Mg levels), 
bolster the idea that water intake(e.g., from tap waters, 
well waters, bottled waters, beverages using tap/well/
spring waters, or distilled waters) in humans should 
contain at least 25-40 mg/liter/day of Mg2+. A number of 
studies done in our labs indicate that most, if not all of 
the cardiovascular manifestations (i.e.,decreased cardiac 
output, decreased coronary flows, decreased myocardial 
contractility, lipid peroxidation of cardiac and coronary 
VSM cell membranes, synthesis/release of toxic ceramides 
, PAF, cytokines, and chemokines , as well as Ca2+overload, 
myocardial acidification, loss of ATP, and apoptosis) 
observed in hearts of experimental animals fed low dietary 
Mg intake, can either be prevented or greatly ameliorated 
when the animals imbibe drinking waters with appropriate 
amounts of Mg2+. We are convinced the latter inclusion 
in our diets and those of all cancer patients should go a 
long-way towards the prevention and amelioration of atrial 
and ventricular arrhythmias, decreased cardiac output 
and contractility, increased coronary vascular resistance, 
hypertension, and cardiac ischemic events leading to IHD 
and SCD. In this context, it is of particular interest to note 
that several clinical studies have shown some positive 
effects of Mg therapy( either prophylactic or orally 
administered)  in several types of cancer patients treated 
with PBCDs.
Conclusions
 Although the exact cause(s) of PBCD-induced 
cardiomyopathy, cardiac failure and SCD in cancer 
patients is not known, Mg2+-depletion is clearly observed 
in many of these treated subjects. Experimentally, low 
dietary intake of Mg or animals given PBCDs demonstrate 
most, if not all, of the pathophysiological cardiovascular 
effects observed in cancer patients given these antitumor 
drugs. Generation/ release of ceramides and PAF, as well 
as PAF-like lipids, appear to be critically-involved in the 
cardiovascular effects of Mg-deficiency and most likely in 
PBCD-indiuced cardiac manifestations in patients. In view 
of our data, and hypothesis, it would probably be prudent 
to undertake clinical trials to determine if antagonists of 
SMases, SPT 1 and SPT 2, as well as antagonists of PAF 
would, along with Mg supplementation, reduce markedly 
the incidence and severity of cardiac problems in patients 
treated with PBCDs. 
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